New generation vs. first generation antipsychotics debate: Pragmatic clinical trials and practice-based evidence

Psychiatria Danubina

Volumn 21, Issue 4, 2009, Pages 446-452

  Jakovljević, Miro ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Antipsychotics; Clinical trials; Effectiveness; Personalized medicine

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; DROPERIDOL; FLUPENTIXOL; FLUPENTIXOL DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIPOTIAZINE PALMITATE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL;

CLINICAL DECISION MAKING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; MENTAL HEALTH; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PSYCHOSIS; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; DRUG INDUSTRY; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCIENTIFIC MISCONDUCT; TREATMENT OUTCOME;

EID: 72849126560     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Azrin ST & Goldman HH: Evidence-based practice emerges. In Drake RE, Merrens MR & Lynde DW (eds.): Evidence-Based Mental Health Practice - A Textbook, 67-93. W. W. Norton & Company, London 2005.
2. Emsley R & Oosthuizen P: Evidence-based pharmacotherapy of schizophrenia. In Stein D, Lerer B, & Stahl S (eds.): Evidence-Based Psychopharmacology, 56-87, Cambridge University Press, 2005.
3. Fleischhacker WW & Goodwin GM: Effectiveness as an outcome measure for treatment trials in psychiatry. World Psychiatry 2009; 8:23-27.
4. Fleischhacker WW, Keet IP, Kahn RS et al.: The European First Episode Schizophrenia Trial (EUFEST):r rationale and design of the trial. Schizophrenia Research 2005; 78:147-156.
5. Geddes J, Freemantle N, Harrison P, Bebbington P for the National Schizophrenia Guideline Development Group: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321:1371-1376.
6. Institute of Medicine: Crossing the quality chasm: A new health system for the 21st century. National Academy Press, Washington DC, 2001.
7. Jakovljević M: Psychopharmacotherapy and comorbidity: Conceptual and epistemiological issues, dilemmas and controversies. Psychiatria Danubina 2009; 21:333-340.
8. Jakovljevic M: Transdisciplinary holistic integrative psychiatry - A wishful thinking or reality? Psychiatria Danubina 2008; 20:341-348.
9. Jakovljevic M: Contemporary psychopharmacotherapy in the context of brave new psychiatry, well-being therapy and life coaching. Psychiatria Danubina 2007a; 19:195-201.
10. Jakovljević M: Myths and facts in contemporary psychopharacotherapy - Evidence-base vs. evidence-biased treatment algorithms practice. Psychiatria Danubina 2007b; 19:342-349.
11. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A & Lewis SW: Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006; 63:1079-1087.
12. Kahn RS, Fleischhacker WW, Boter H, et al.: Effectivenes of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008; 371:1085-1097.
13. Laugharne R: Evidence - the postmodern perspective. In Priebe S & Slade M (eds): Evidence in Mental Health Care, 53-56.Brunner-Routledge, Hove and New York, 2004.
14. Leucht S, Engel RR, Baeuml J & Davis JD: Is the efficacy of new generation antipsychotics an artifact of LOCF? Schizophrenia Bulletin 2007; 33:183-191.
15. Lewis SW, Barnes TR, Davies L, et al.: Randomized controlled trial of effect of prescription of clozapine versus other second generation antipsychotic drugs in resistant schizophrenia. Evid Based Ment Health 2007; 10:57
16. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J & Hsiao JK for the CATIE investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223
17. Marschall M: Randomised controlled trials - misunderstanding, fraud and spin. In Priebe S & Slade M (eds): Evidence in Mental Health Care, 59-71. Brunner-Routledge, Hove and New York, 2004.
18. McEvoy JP, Lieberman JA, Perkins DO, et al.: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double blind 52-week comparison. Am J Psychiatry 2007; 164:1050-1060. (Pubitemid 47121394)
19. Moeller HJ: Do effectiveness («real world»)studies on antipsychotics tell us the real truth? Eur Arch Psychiatry Clin Neurosci 2008; 258:257
20. Moeller HJ: Do «real world» studies on antipsychotics tell us the real truth. World Psychiatry 2009; 8:32.
21. Nasrallah H & Tandon R: Classic antipsychotic medications. In Schatzberg AF & Nemeroff CB (eds): The American Psychiatric Publishing Textbook of Psychopharmacology, 533-554. IV edition. American Psychiatric Publishing, Inc., Washington, DC, 2009
22. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, et al: Effectiveness et cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized control trial. JAMA 2003; 290:2693-2702. (Pubitemid 37475597)
23. Sartorius N, Fleischhacker WW, Gjerris A, Kern U, Knapp M, Leonhard BE, Lieberman JA, Lopez-Ibor JJ, van Raay B &Tworney E: The usefulness and use of second generation antipsychotic medications - an update. Curr Opin Psychiatry 2003(suppl. 1); 16:s1-s44.
24. Shiloh R, Nutt D & Weizman A: Atlas of Psychiatric Psychopharmacotherapy. Martin Dunitz, London, 1999.
25. Siegfried K: Clinical development of atypical antipsychotics. Good Clinical Practice Journal 2001; 8:20-26.
26. Tandon R & Fleischhacker WW: Comparative efficacy of antipsychotics in the treatment of schizophrenia: A critical assessment. Schizophrenia Research 2005; 79:145-155. (Pubitemid 41457255)
27. Thompson IE: A corporate approach to ethics in medicine. In Phillips CI (ed): Logic in Medicine, 170-192, BMJ Publishing Group, London, 1995.